financetom
Business
financetom
/
Business
/
Oklo Stock Is Rising Again: What's Going On?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Oklo Stock Is Rising Again: What's Going On?
Jun 17, 2025 7:31 AM

Oklo Inc ( OKLO ) shares are trading higher Tuesday after the company announced subsidiary Atomic Alchemy commenced site characterization work at a potential location for a commercial radioisotope production facility.

What To Know: Nuclear startup Oklo ( OKLO ) announced the start of site characterization activities at the Idaho National Laboratory, which includes core borings to collect soil and rock samples. The samples are expected to provide its subsidiary Atomic Alchemy data on subsurface composition with the aim of ensuring the facility meets requirements.

The progress milestone follows prior approvals and agreements and is another step toward establishing a radioisotope production site to position the U.S. at the forefront of nuclear technology development.

Oklo ( OKLO ) said radioisotopes are expected to represent a $55.7 billion market opportunity by 2026, according to Research Nester.

“Oklo aims to address this growing market demand through reliable, U.S.-based radioisotope production facilities that leverage our nuclear reactor and fuel recycling technologies,” said Jacob DeWitte, co-founder and CEO of Oklo ( OKLO ).

“Through Atomic Alchemy, we aim to execute transformative projects that will expand our capabilities in commercial radioisotope production.”

Oklo ( OKLO ) said last week that the U.S. Nuclear Regulatory Commission initiated a review of its licensed operator topical report as the company continues to progress on its combined license application seeking approval to operate its planned Aurora powerhouses.

Oklo ( OKLO ) further announced that it was issued a Notice of Intent to Award by the Defense Logistics Agency Energy to deploy one of its planned Aurora powerhouses at an Air Force installation in Alaska.

Oklo ( OKLO ) is targeting late 2027 or early 2028 for deployment of its first nuclear powerhouse.

OKLO Price Action: Oklo ( OKLO ) shares were up 3.47% at $67.72 at the time of publication Tuesday. Oklo ( OKLO ) has been moving on strong momentum in recent months as the stock continues to hit new highs. Oklo ( OKLO ) has a momentum score of 99.37 according to Benzinga Pro. Oklo ( OKLO ) shares are now up about 208% year-to-date.

Read Next:

AI, Quantum Tech Could Heighten Nuclear Conflict Risk Through ‘Miscommunication’ And ‘Technical Accidents,’ Warns Think Tank

Sunrun, First Solar Plunge—Solar Stocks Hit Hard By Trump Tax Bill: Latest

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Hilton, Explora Journeys Launch Luxury Ocean Travel Partnership
Hilton, Explora Journeys Launch Luxury Ocean Travel Partnership
Mar 10, 2026
08:51 AM EST, 12/08/2025 (MT Newswires) -- Hilton (HLT) and Explora Journeys said Monday the companies will partner to allow Hilton Honors members to earn and redeem points on the cruise operator's voyages from summer 2026. Explora Journeys, the MSC Group's luxury ocean travel brand, operates two ships with plans for six ships by 2028, the companies said. The partnership...
Sector Update: Consumer
Sector Update: Consumer
Mar 10, 2026
08:55 AM EST, 12/08/2025 (MT Newswires) -- Consumer stocks were declining premarket Monday, with the Consumer Staples Select Sector SPDR Fund (XLP) 0.1% lower and the Consumer Discretionary Select Sector SPDR Fund (XLY) down 0.3%. Unilever ( UL ) spin-off The Magnum Ice Cream Co. said its shares will begin trading on the New York Stock Exchange on Monday under...
Agios Pharmaceuticals' Supplemental NDA for Mitapivat to Treat Thalassemia Still Under FDA Review
Agios Pharmaceuticals' Supplemental NDA for Mitapivat to Treat Thalassemia Still Under FDA Review
Mar 10, 2026
08:50 AM EST, 12/08/2025 (MT Newswires) -- Agios Pharmaceuticals ( AGIO ) said Monday that the US Food and Drug Administration has not yet issued a regulatory decision on the supplemental New Drug Application for mitapivat to treat adults with the blood disorder thalassemia. The biopharmaceutical company said the sNDA remains under active review, with an FDA-issued Prescription Drug User...
LATAM Airlines Reports 3.6% Increase in November Traffic
LATAM Airlines Reports 3.6% Increase in November Traffic
Mar 10, 2026
08:54 AM EST, 12/08/2025 (MT Newswires) -- LATAM Airlines Group ( LTM ) said Monday that consolidated passenger traffic, measured in revenue passenger kilometers, rose 3.6% year over year in November. System capacity, measured in available seat kilometers, increased 4.6% from a year earlier, with load factor of 85.4% for the month, the company said. For its cargo operations, the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved